Stephanie Reuter
stephanie.reuter@hartmann.info
+49 173 3453885
Heidenheim, 20 November 2024. In the first nine months of 2024, the HARTMANN GROUP continued to perform well in a challenging market environment with demanding sales markets. From January to September 2024, organic sales growth of 3.1% led to sales revenues of EUR 1,796.8 million. The positive sales development is mainly due to the introduction of new products as part of the Transformation Program, which offer significant added value for HARTMANN customers.
At EUR 214.0 million, adjusted EBITDA was up EUR 66.9 million on the prior-year figure. The Transformation Program again made a significant contribution to earnings, both through the development of innovative products and structural cost measures. Material, freight and energy costs remained at a high level. In addition, HARTMANN is pursuing a cautious cost management policy due to the many uncertainties in the markets.
On the whole, however, the economic conditions have stabilized compared to the previous year. This allows the positive effects of the Transformation Program to take full effect.
The Incontinence Management segment was able to further increase its sales growth with incontinence pants in important European countries and in Australia.
The Wound Care segment continued to grow in the strategic growth area of advanced wound care supported by the launch of new siliconized wound dressings, particularly in France, the United States and Germany.
The Infection Management segment recorded different developments. Lower market prices for examination and surgical gloves and personal protective equipment led to a decline in sales. By contrast, the Company recorded strong sales growth in surface disinfection in particular. In Germany and Switzerland, market share was gained in the pharmacy business.
In the Complementary Group Divisions segment, CMC achieved strong growth. KOB also saw growth. Kneipp maintained its sales at the same level of the previous year.
HARTMANN will continue to focus on the course set by the Transformation Program in the future. The program, which is developing positively, is expected to approximately contribute an additional EUR 50 million to earnings in 2024. It will further strengthen the Company’s competitiveness and resilience.
On the basis of the business performance in 2024 to date, along with current forecasts and cautious cost management, HARTMANN is raising its outlook for adjusted EBITDA from between EUR 220 and 260 million to between EUR 230 and 270 million. The Company continues to expect moderate organic sales growth for the financial year.
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.